Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Revotar Wins Roughly $3.65M to Progress Selectin Antagonists Against Respiratory Conditions

Company’s lead inhibitor is progressing through Phase II trials in asthma, COPD, and psoriasis.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »